ESCRS - PO396 - Impact Of Minimally Invasive Glaucoma Surgery On The Ocular Surface And Quality Of Life In Patients With Glaucoma.

Impact Of Minimally Invasive Glaucoma Surgery On The Ocular Surface And Quality Of Life In Patients With Glaucoma.

Published 2022 - 40th Congress of the ESCRS

Reference: PO396 | Type: Free paper | DOI: 10.82333/qxyr-r768

Authors: Lee Jones* 1 , Natalia Maes 2 , Umair Qidwai 3 , Gokulan Ratnarajan 3

1Institute of Ophthalmology,UCL,London,United Kingdom, 2Brighton and Sussex University Hospitals NHS Trust,Brighton,United Kingdom, 3Queen Victoria Hospital NHS Foundation Trust,East Grinstead,United Kingdom

Purpose

The purpose of this study was to explore the impact of minimally invasive glaucoma surgery (MIGS) on patient-reported outcomes and clinical parameters related to ocular surface disease in people with glaucoma.

Setting

Queen Victoria Hospital NHS Foundation Trust glaucoma service

Methods

Fifty-seven patients completed quality of life outcome measures and clinical examination of the ocular surface at baseline prior to undergoing iStent combined with phacoemulsification with or without adjunctive endocyclophotocoagulation and repeated the measures at 4-month follow-up. 

Results

At follow-up, on average patients returned statistically significantly improved scores on glaucoma-specific (GQL-15, p=<0.001; GSS, p=<0.001), general health (EQ5D, p=0.02) and ocular surface PROMs (OSDI, p=0.001). Patients were using fewer eye drops on average after MIGS compared to before surgery (1.1 ± 0.9 versus 1.8 ± 0.8; p = <0.001). Undergoing MIGS was associated with improved tear film break-up time (p = <0.001) and reduced corneal fluorescein staining (p = <0.001).

Conclusions

Quality of life and clinical parameters related to the ocular surface are improved following MIGS combined with phacoemulsification in patients previously treated with anti-glaucoma therapy.